New: Instantly spot drawdowns, dips, insider moves, and breakout themes across Maps and Screener.

Verrica Pharmaceuticals Inc.

Contributing Author

Recent Articles by Verrica Pharmaceuticals Inc.

Jan-07	Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH (VP-102) for the Treatment of Common Warts VRCA GlobeNewswire
Nov-24	Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway VRCA GlobeNewswire
Nov-14	Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results VRCA GlobeNewswire
Nov-10	Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting VRCA GlobeNewswire
Oct-20	Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH in the European Union VRCA GlobeNewswire
Oct-07	Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting VRCA GlobeNewswire
Sep-19	Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH (TO-208) in Japan for the Treatment of Molluscum Contagiosum VRCA GlobeNewswire
Sep-02	Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference VRCA GlobeNewswire
Aug-12	Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results VRCA GlobeNewswire
Aug-06	Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025 VRCA GlobeNewswire
Jul-09	Verrica Pharmaceuticals Reports Strong Growth in YCANTH Dispensed Applicator Units in 2Q 2025 VRCA GlobeNewswire
Jul-01	Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH for the Treatment of Common Warts VRCA GlobeNewswire
May-28	Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York VRCA GlobeNewswire
May-13	Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results VRCA GlobeNewswire
May-07	Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025 VRCA GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.